表紙
市場調查報告書
商品編碼
630031

人類生長激素缺乏症 (GHD) 治療藥的全球市場:現狀,開發中產品分析,臨床實驗趨勢,市場潛在力 - 未來預測

Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023

出版日期: | 出版商: Azoth Analytics | 英文 130 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供人類生長激素缺乏症 (hGHD)的治療藥的市場相關分析,與生長激素缺乏症 (GHD)的概要和主要的治療手段,現在臨床實驗中主要的開發中產品的概要,到目前為止的臨床實驗的發展情形,市場規模趨勢預測,各終端用戶、各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業的簡介主要產品等資訊彙整,為您概述為以下內容。

第1章 分析方法

第2章 摘要整理

第3章 生長激素缺乏症治療藥:概要

  • 生長激素 (GH) 與其功能
  • 生長激素缺乏症 (GHD) 與其症狀
  • 生長激素缺乏症 (GHD) 的原因

第4章 生長激素缺乏症 (GHD)的診斷方法

第5章 生長激素缺乏症 (GHD)的治療方法

第6章 全球生長激素藥品的市場

  • 市場規模的成果值 (以金額為準,過去5年份)
  • 市場規模的預測值 (以金額為準,今後6年份)

第7章 全球生長激素缺乏症治療藥的市場

  • 市場規模的成果值 (以金額為準,過去5年份)
  • 市場規模的預測值 (以金額為準,今後6年份)

第8章 全球生長激素缺乏症治療藥的市場:各終端用戶

  • 各終端用戶的市場佔有率 (%):最新值、預測值
  • 兒童用
  • 成人用
    • 市場規模的成果值 (以金額為準,過去5年份)
    • 市場規模的預測值 (以金額為準,今後6年份)

第9章 全球生長激素缺乏症治療藥的市場:各地區

  • 北美市場
  • 歐洲市場
  • 其他的國家 (RoW)的市場
    • 市場規模的成果值 (以金額為準,過去5年份)
    • 市場規模的預測值 (以金額為準,今後6年份)

第10章 全球生長激素缺乏症治療藥的市場:各國

  • 美國市場
  • 英國市場
  • 法國市場
  • 德國市場
  • 西班牙市場
  • 日本市場
    • 市場規模的成果值 (以金額為準,過去5年份)
    • 市場規模的預測值 (以金額為準,今後6年份)

第11章 人類生長激素缺乏症 (hGHD)的開發中產品:分析

  • TransCon-hGH
    • 概要
    • 法規的里程碑
    • 優點、缺點
    • 產品簡介與上市預定日
    • 臨床實驗趨勢與現狀
    • 重要的臨床實驗與其結果
    • 全球市場的潛在的規模
  • Somapacitan
  • Somavaratan
  • Somatrogon/Lagova
  • 競爭環境

第12章 企業簡介

  • Ascendis Pharma A/S
  • Novo Nordisk A/S
  • Versartis Inc.
  • Opko Health, Inc.
  • Pfizer Inc
目錄

The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD). These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.

The report titled "Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.

Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.

The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 - 2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs. The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.

Scope of the Report

Global Market

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Assessment - TransCon-hGH, Somapacitan, Somavaratan, Somatrogon (Forecast Period: 2020-2023)

  • Market Potential
  • Clinical Trials
  • Product Description
  • Regulatory Phases
  • 7Ps Analysis

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market - Sizing and Growth

  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023

Regional Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market - Sizing and Growth: North America, Europe, Rest of the World

  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023

Country Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market - Sizing and Growth: US, UK, France, Spain, Germany, Japan

  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023

Other Report Highlights

  • Company Analysis - Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Growth Hormone Deficiency Drugs Product - An Overview

  • 3.1. Growth Hormone (GH) and its Function
  • 3.2. Growth Hormone Deficiency (GHD) and its Symptoms
  • 3.3. Causes of Growth Hormone Deficiency (GHD)

4. Diagnosis of Growth Hormone Deficiency (GHD)

5. Treatment of Growth Hormone Deficiency (GHD)

6. Global Growth Hormone Drugs Market

  • 6.1. Global Growth Hormone Drugs Market Size, By value, 2013-2017
  • 6.2. Global Growth Hormone Drugs Market Size, By value, 2018-2023

7. Global Growth Hormone Deficiency Drugs Market

  • 7.1. Global Growth Hormone Deficiency Drugs Market Size, By value, 2013-2017
  • 7.2. Global Growth Hormone Deficiency Drugs Market Size, By value, 2018-2023

8. Global Growth Hormone Deficiency Drugs Market, By End User

  • 8.1. Global Growth Hormone Deficiency Drugs Market, By End User: Break down (%)
    • 8.1.1. Global Growth Hormone Deficiency Drugs Market, By End User: 2017%
    • 8.1.2. Global Growth Hormone Deficiency Drugs Market, By End User: 2023%
  • 8.2. Global Growth Hormone Deficiency Drugs Market, By End User - By Pediatrics
    • 8.2.1. By Value (2013 - 2017)
    • 8.2.2. By Value (2018 - 2023)
  • 8.3. Global Growth Hormone Deficiency Drugs Market, By End User - By Adult
    • 8.3.1. By Value (2013 - 2017)
    • 8.3.2. By Value (2018 - 2023)

9. Global Growth Hormone Deficiency Drugs Market: Regional Analysis

  • 9.1. North America Growth Hormone Deficiency Drugs Market
    • 9.1.1. By Value (2013 - 2017)
    • 9.1.2. By Value (2018 - 2023)
  • 9.2. Europe Growth Hormone Deficiency Drugs Market
    • 9.2.1. By Value (2013 - 2017)
    • 9.2.2. By Value (2018 - 2023)
  • 9.3. ROW Growth Hormone Deficiency Drugs Market
    • 9.3.1. By Value (2013 - 2017)
    • 9.3.2. By Value (2018 - 2023)

10. Global Growth Hormone Deficiency Drugs Market: Country Analysis

  • 10.1. U.S. Growth Hormone Deficiency Drugs Market
    • 10.1.1. By Value (2013 - 2017)
    • 10.1.2. By Value (2018 - 2023)
  • 10.2. U.K. Growth Hormone Deficiency Drugs Market
    • 10.2.1. By Value (2013 - 2017)
    • 10.2.2. By Value (2018 - 2023)
  • 10.3. France Growth Hormone Deficiency Drugs Market
    • 10.3.1. By Value (2013 - 2017)
    • 10.3.2. By Value (2018 - 2023)
  • 10.4. Germany Growth Hormone Deficiency Drugs Market
    • 10.4.1. By Value (2013 - 2017)
    • 10.4.2. By Value (2018 - 2023)
  • 10.5. Spain Growth Hormone Deficiency Drugs Market
    • 10.5.1. By Value (2013 - 2017)
    • 10.5.2. By Value (2018 - 2023)
  • 10.6. Japan Growth Hormone Deficiency Drugs Market
    • 10.6.1. By Value (2013 - 2017)
    • 10.6.2. By Value (2018 - 2023)

11. human Growth Hormone Deficiency (hGHD) Pipeline Drugs - An Analysis

  • 11.1. hGHD Pipeline Drugs - TransCon-hGH
    • 11.1.1. Description
    • 11.1.2. Regulatory Milestones
    • 11.1.3. Advantages & Disadvantages
    • 11.1.4. Product Profile & Launch Date
    • 11.1.5. Clinical Trials and Status
    • 11.1.6. Pivotal Clinical Trials and Results
    • 11.1.7. TransCon-hGH - Global Market Potential
    • 11.1.8. TransCon-hGH - Global Market Potential
  • 11.2. hGHD Pipeline Drugs - Somapacitan
    • 11.2.1. Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Advantages & Disadvantages
    • 11.2.4. Product Profile & Launch Date
    • 11.2.5. Clinical Trials and Status
    • 11.2.6. Pivotal Clinical Trials and Results
    • 11.2.7. Somapacitan - Global Market Potential
    • 11.2.8. Somapacitan - 7Ps Analysis
  • 11.3. hGHD Pipeline Drugs - Somavaratan
    • 11.3.1. Description
    • 11.3.2. Regulatory Milestones
    • 11.3.3. Advantages & Disadvantages
    • 11.3.4. Product Profile & Launch Date
    • 11.3.5. Clinical Trials and Status
    • 11.3.6. Pivotal Clinical Trials and Results
    • 11.3.7. Somavaratan - Global Market Potential
    • 11.3.8. Somavaratan - 7Ps Analysis
  • 11.4. hGHD Pipeline Drugs - Somatrogon/ Lagova
    • 11.4.1. Description
    • 11.4.2. Regulatory Milestones
    • 11.4.3. Advantages & Disadvantages
    • 11.4.4. Product Profile & Launch Date
    • 11.4.5. Clinical Trials and Status
    • 11.4.6. Pivotal Clinical Trials and Results
    • 11.4.7. Somatrogon/ Lagova - Global Market Potential
    • 11.4.8. Somatrogon/ Lagova - 7Ps Analysis
  • 11.5. Competitive Landscape

12. Company Profiles

  • 12.1. Ascendis Pharma A/S
  • 12.2. Novo Nordisk A/S
  • 12.3. Versartis Inc.
  • 12.4. Opko Health, Inc.
  • 12.5. Pfizer Inc

List of Figures

  • Figure 1: Global Growth Hormones Drugs Market Size, By value, 2013-2017 (USD Billion)
  • Figure 2: Global Growth Hormones Drugs Market Size, By value, 2018-2023 (USD Billion)
  • Figure 3: Global Growth Hormones Market Share 2017
  • Figure 4: Sales of Growth Hormones, By Value, 2014-2017
  • Figure 5: Global Growth Hormone Market Share, 2017 (%)
  • Figure 6: Global Growth Hormones Deficiency Drugs Market Size, By value, 2013-2017 (USD Billion)
  • Figure 7: Global Growth Hormones Deficiency Drugs Market Size, By value, 2018-2023 (USD Billion)
  • Figure 8: Global Growth Hormone Market 2017
  • Figure 9: Global Growth Hormone Market 2028
  • Figure 10: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2017 (%)
  • Figure 11: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2023 (%)
  • Figure 12: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2013-2017 (USD Billion)
  • Figure 13: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2018-2023 (USD Billion)
  • Figure 14: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2013-2017 (USD Billion)
  • Figure 15: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2018-2023 (USD Billion)
  • Figure 16: North America Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 17: Europe Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 18: ROW Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 19: US Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 20: U.S. Per Capita Health Expenditure, 2012-2016 (USD)
  • Figure 21: U.S Prevalence of Cancer, in cases per 100,000 (2014-2016)
  • Figure 22: UK Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 23: France Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 24: France Per Capita Healthcare Expenditure (USD)
  • Figure 25: France Prevalence of Cancer, in cases per 100,000 (2014-2016)
  • Figure 26: Germany Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 27: Germany Healthcare Expenditure (USD Billion, 2014-2017
  • Figure 28: Germany Prevalence of Cancer, in cases per 100,000 (2014-2016)
  • Figure 29: Spain Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 30: Japan Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 31: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
  • Figure 32: Change in HT SDS (Mean + SD) of full dataset of 53 patients after 6 months of treatment
  • Figure 33: Dose Proportional IGF-1 Elevation Observed into the Normal Range
  • Figure 34: Comparable hGH levels for TransCon Growth Hormone and Daily hGH
  • Figure 35: Global TransCon hGH Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 36: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
  • Figure 37: Global Somapacitan (NN8640) Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 38: Height Velocity at 12 months in ITT and PP groups
  • Figure 39: Global Somavaratan (VRS-317) Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 40: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
  • Figure 41: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
  • Figure 42: Global Somatrogon (Lagova) Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 43: Ascendis Pharma Company Net Sales, By Value, in million €
  • Figure 44: Novo Nordisk Company Net Sales, By Value, in million DKK
  • Figure 45: Norditropin® net sales, by value, in million DKK
  • Figure 46: Pfizer Company Revenue, By Value, in million USD
  • Figure 47: Genotropin net sales, by value, in million USD

List of Tables

  • Table A: Upcoming Drugs in the market of Growth Hormone Deficiency and their Clinical Status from 2016 - 2020